Peak Bio, Inc. announced that it has entered into a securities purchase agreement to issue convertible note on December 18, 2023. The company may close the transaction in one or two tranches. The company shall, at each closing of the offering of the Convertible Notes, pay a cash commission equal to 8% of the gross proceeds received by the Company from Qualified Investors from such closing.